Passage Bio, Inc. (PASG) Financial Statements (2024 and earlier)

Company Profile

Business Address ONE COMMERCE SQUARE
PHILADELPHIA, PA 19103
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments189,610,000315,773,000304,817,000
Cash and cash equivalents34,601,000128,965,000135,002,000
Short-term investments155,009,000186,808,000169,815,000
Prepaid expense   1,405,000
Deferred costs   200,000
Other undisclosed current assets7,434,0009,293,00010,761,000
Total current assets:197,044,000325,066,000317,183,000
Noncurrent Assets
Operating lease, right-of-use asset19,723,000  
Property, plant and equipment22,515,00023,806,0002,795,000
Other noncurrent assets4,267,0006,204,0008,029,000
Total noncurrent assets:46,505,00030,010,00010,824,000
TOTAL ASSETS:243,549,000355,076,000328,007,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities13,113,00020,339,00011,168,000
Employee-related liabilities10,014,0005,183,000
Accounts payable4,065,0009,448,0005,265,000
Accrued liabilities9,048,000877,000720,000
Other liabilities 500,000541,000
Other undisclosed current liabilities5,238,0008,659,0009,466,000
Total current liabilities:18,351,00029,498,00021,175,000
Noncurrent Liabilities
Liabilities, other than long-term debt23,832,0006,921,0002,118,000
Deferred rent credit  6,921,0002,077,000
Other liabilities   41,000
Operating lease, liability23,832,000  
Total noncurrent liabilities:23,832,0006,921,0002,118,000
Total liabilities:42,183,00036,419,00023,293,000
Equity
Equity, attributable to parent201,366,000318,657,000304,714,000
Common stock5,0005,0004,000
Additional paid in capital694,733,000675,346,000475,617,000
Accumulated other comprehensive loss(966,000)(413,000)(12,000)
Accumulated deficit(492,406,000)(356,281,000)(170,895,000)
Total equity:201,366,000318,657,000304,714,000
TOTAL LIABILITIES AND EQUITY:243,549,000355,076,000328,007,000

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
Operating expenses(138,394,000)(185,729,000)(112,902,000)
Operating loss:(138,394,000)(185,729,000)(112,902,000)
Nonoperating income
(Investment Income, Nonoperating)
2,269,000343,000670,000
Loss from continuing operations:(136,125,000)(185,386,000)(112,232,000)
Loss before gain (loss) on sale of properties:(185,386,000)(112,232,000)
Net loss:(136,125,000)(185,386,000)(112,232,000)
Other undisclosed net income attributable to parent   
Net loss available to common stockholders, diluted:(136,125,000)(185,386,000)(112,232,000)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
Net loss:(136,125,000)(185,386,000)(112,232,000)
Comprehensive loss:(136,125,000)(185,386,000)(112,232,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(553,000)(401,000)(12,000)
Comprehensive loss, net of tax, attributable to parent:(136,678,000)(185,787,000)(112,244,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: